Aml (Acute Myelogenous Leukemia) Clinical Trials
3 recruiting trials for Aml (Acute Myelogenous Leukemia). Eligibility criteria explained in plain English.
TrialFinderData lists 3 Aml (Acute Myelogenous Leukemia) clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.
Across the trials that carry a phase, Phase 1 is the largest group at 33% (1 studies); the largest phase groups are Phase 1: 1, Phase 2: 1, Phase 3: 1.
Research is led by Cullgen (Shanghai),Inc (1), Institute of Hematology & Blood Diseases Hospital, China (1), Federal Research Institute of Pediatric Hematology, Oncology and Immunology (1), among the most active sponsors registered for these trials.
The most frequently studied intervention is CG009301 for Injection (drug, 1 trial), followed by Avapritinib, azacitidine, Venetoclax, 4 chemotherapy blocks: Course 1 AIE (cytarabine/idarubicin/etoposide), Course 2 AI (cytarabine/idarubicin), Course 3 HAD (high-dose cytarabine (1g)/daunorubicin), Course 4 HA (high-dose cytarabine)..
Track Aml (Acute Myelogenous Leukemia) trials
Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.
Recruiting Trials
Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.
A Phase 1 Study of CG009301 for Injection in Adult Subjects With Recurrent or Refractory Haematological Malignancies
The goal of this clinical trial is to learn about the safety of drug CG009301. It also learns if drug CG009301 works to treat in Participants with relapsed or refractory adult...
Avapritinib Combined With Azacitidine and Venetoclax in the Treatment of Relapsed AML After Allo-HSCT
This is a single-center, prospective, single-arm, exploratory clinical study. To explore the efficacy and safety of avapritinib in patients with recurrent acute myeloid leukemia...
The Efficacy of Therapy in Patients With Acute Myeloid Leukemia and Down Syndrome in Russia
This prospective non-randomized multicenter trial created based on protocol ML DS 2006 and aimed at standardization of current therapy approaches and creating a national network...
Explore Other Conditions
Frequently Asked Questions
There are currently 3 clinical trials for Aml (Acute Myelogenous Leukemia), with 3 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.
To join a clinical trial for Aml (Acute Myelogenous Leukemia), review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.
Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 1 Phase 3 trials for Aml (Acute Myelogenous Leukemia), representing treatments closest to potential FDA approval.
Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.
Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.